Clinical Trial Update: Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating tachyphylaxis, tolerance, and withdrawal after treatment with intranasal dexmedetomidine (Igalmi) for agitation in schizophrenia or bip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• IGALMI (DEXMEDETOMIDINE)

Snippet

Sponsor: BioXcel Therapeutics Inc | Conditions: Bipolar Disorder, Schizophrenia | Phase 4 | Status: COMPLETED | Results posted: 2026-01-02